Wilhelm Huisinga
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nassar Y, Ojara F, Pérez-Pitarch A, Geiger K, Huisinga W, Hartung N, Michelet R, Holdenrieder S, Jörger M, Kloft C. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. Cancers (Basel) 2023; 15
Nov 15, 2023C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nov 15, 2023Cancers (Basel) 2023; 15
Nassar Yomna M, Ojara Francis Williams, Pérez-Pitarch Alejandro, Geiger Kimberly, Huisinga Wilhelm, Hartung Niklas, Michelet Robin, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Jörger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725.
Feb 27, 2023A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Feb 27, 2023CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725
Ojara Francis Williams, Henrich Andrea, Frances Nicolas, Nassar Yomna M, Huisinga Wilhelm, Hartung Niklas, Geiger Kimberly, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Klopp-Schulze L, Michelet R, Kloft C. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. Cancers (Basel) 2021; 13
May 18, 2021Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
May 18, 2021Cancers (Basel) 2021; 13
Mueller-Schoell Anna, Mikus Gerd, Huisinga Wilhelm, Jörger Markus, Schwab Matthias, Mürdter Thomas E, van Dyk Madelé, Klopp-Schulze Lena, Michelet Robin, Kloft Charlotte
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Michelet R, Klopp-Schulze L, Kloft C. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals (Basel) 2021; 14
Feb 3, 2021Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
Feb 3, 2021Pharmaceuticals (Basel) 2021; 14
Mueller-Schoell Anna, Mikus Gerd, Huisinga Wilhelm, Jörger Markus, Schwab Matthias, Mürdter Thomas E, van Dyk Madelé, Michelet Robin, Klopp-Schulze Lena, Kloft Charlotte
Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
Ojara F, Henrich A, Frances N, Huisinga W, Hartung N, Jörger M, Kloft C. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. J Pharmacol Exp Ther 2020; 375:430-438.
Oct 2, 2020Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
Oct 2, 2020J Pharmacol Exp Ther 2020; 375:430-438
Ojara Francis W, Henrich Andrea, Frances Nicolas, Huisinga Wilhelm, Hartung Niklas, Jörger Markus, Kloft Charlotte
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Mueller-Schoell A, Schwab M, Zgheib N, Tfayli A, Chowbay B, Chen S, Eccles D, Copson E, Mathijssen R, Koolen S, Neven P, Jörger M, Huisinga W, Brauch H, Michelet R, Mürdter T, Schroth W, Klopp-Schulze L, Kloft C. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clin Pharmacol Ther 2020; 108:661-670.
Jul 23, 2020Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Jul 23, 2020Clin Pharmacol Ther 2020; 108:661-670
Mueller-Schoell Anna, Schwab Matthias, Zgheib Nathalie K, Tfayli Arafat, Chowbay Balram, Chen Sylvia, Eccles Diana, Copson Ellen, Mathijssen Ron H J, Koolen Stijn L W, Neven Patrick, Jörger Markus, Huisinga Wilhelm, Brauch Hiltrud, Michelet Robin, Mürdter Thomas, Schroth Werner, Klopp-Schulze Lena, Kloft Charlotte
Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Henrich A, Jörger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362:347-358.
Jun 9, 2017Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Jun 9, 2017J Pharmacol Exp Ther 2017; 362:347-358
Henrich Andrea, Jörger Markus, Kraff Stefanie, Jaehde Ulrich, Huisinga Wilhelm, Kloft Charlotte, Parra-Guillen Zinnia Patricia